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Epidermal growth factor receptor (EGFR) or ErbB receptor family
members, including EGFR, ErbB-2, ErbB-3, and ErbB-4, are
glycosylated transmembrane proteins with tyrosine kinase
domains (Ullrich et al, 1984; Bargmann et al, 1986; Kraus et al,
1989; Plowman et al, 1990). Ligands, such as EGF or heregulin
(HRG) neu differentiation factor (NDF)/neuregulin (NRG), acti-
vate ErbB family members by inducing homo- or heterodimeriza-
tion amongst receptor members, resulting in stimulation of
tyrosine kinase activity and initiation of signalling pathways
(Goldman et al, 1990; Kim et al, 1994). ErbB family members are
frequently overexpressed in human carcinomas including those of
the breast, stomach, lung, ovary and pancreas (Slamon et al, 1987;
Gullick, 1991; Lemoin et al, 1992). Overexpression of EGFR and
ErbB-2 is closely associated with poor prognosis in breast cancer
(Slamon et al, 1989). ErbB-3, a 180 kDa glycosylated transmem-
brane protein, was identified based on its amino acid identity to
other EGFR family members (Kraus et al, 1989). The tyrosine
kinase activity of ErbB-3 is at least two orders of magnitude less
than that of the EGFR due to amino acid substitutions in the
conserved tyrosine kinase domain (Guy et al, 1994).
HRG/NDF, a 44 kDa glycosylated transmembrane protein, was
originally identified as a ligand for ErbB-2 on the basis of its
ability to induce ErbB-2 tyrosine phosphorylation (Holmes et al,
1992; Peles et al, 1992; Bacus et al, 1993). However, biochemical
and functional studies have demonstrated that ErbB-3 and ErbB-4
are receptors for HRG/NDF of differing affinity (Carraway et al,
1994; Sliwkowski et al, 1994). HRG/NDF binding to the extra-
cellular domain of ErbB-3 stimulates tyrosine phosphorylation of
ErbB-3 (Carraway et al, 1995). Tyrosyl phosphorylated ErbB-3
couples to phosphatidyl-inositol 3-kinase (PI3-kinase) through the
interaction between phosphotyrosines in the receptor’s cyto-
plasmic tail and the SH2 domain of PI3-kinase (p85) to mediate
many of the biological responses to HRG/NDF (Fedi et al, 1994;
Soltoff et al, 1994; Gamett et al, 1995; Marte et al, 1995).
Apart from receptor phosphotyrosine-SH2 or PTB domain inter-
actions, increasing data suggest that there are non-phosphorylated
receptor–substrate interactions controlled by ligand stimulation.
For example, eps8, a 92 kDa SH3 domain containing protein, has
been identified as a substrate for the EGFR based on its associa-
tion with the EGFR juxtamembrane domain after EGF stimulation
(Fazioli et al, 1993). Interestingly, a mutant EGFR, lacking a
kinase domain, still associates with eps8, suggesting the possi-
bility of pre-existing substrate–receptor complexes in the absence
of tyrosine kinase activity (Castagnino et al, 1995). Furthermore,
the association of a nuclear localizing zinc-finger protein, ZPR1,
with the cytoplasmic tyrosine kinase domain of the EGFR, is
decreased by EGF stimulation of EGFR tyrosine kinase activation
(Galcheva-Gargova et al, 1996).
The molecular mechanisms by which HRG/NDF-induces
signalling through the kinase inactive ErbB-3 receptor are not
clear. The yeast-two hybrid system (Fields and Song, 1989) was
used to characterize proteins that interact with ErbB-3 in the
absence of tyrosine phosphorylation. We report that the protein
(Ebp1) predicted to be encoded by the recently cloned human
PA2G4 gene binds ErbB-3. This protein is the human homologue
of the mouse p38-2G4 protein, a cell cycle-regulated DNA binding
protein (Radomski and Jost, 1995; Lamartine et al, 1997). The
gene encoding a curved DNA binding protein from
Saccharomyces pombe also shows homology to members of the
PA2G4 gene family (Yamada et al, 1994). In this paper we show
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DOI: 10.1054/ bjoc.1999.0981, available online at http://www.idealibrary.com on that Ebp1 associates with the juxtamembrane domain of ErbB-3 in
a tyrosine kinase-independent manner. Ebp1 dissociates from
ErbB-3 after HRG activation and translocates to the nucleus.
MATERIALS AND METHODS
Construction of the bait vector
The cytoplasmic domain of erbB3 (amino acids 665–1339;
nucleotides 2131–4155) (provided by Dr John Koland, University
of Iowa) (Hellyer et al, 1995), which was originally cloned in
pBS-rB3, was amplified by polymerase chain reaction (PCR)
using an EcoRI-overhang 5¢-primer (5¢-GCTAGAATTCCGTG-
GACGCAGGATTCAGAAC-3¢) and a BamHI overhang 3¢-primer
(5¢-ACTAGGATCCCGTTCTCTGGGCATTAGCCTT-3¢). A 2 kb
PCR product of the cytoplasmic domain of erbB3 was direction-
ally subcloned into the EcoRI and BamHI unique restriction
endonuclease sites of the LexA DNA binding domain vector
pEG202 (pEG202/erbB3) (provided by Dr Roger Brent, Harvard
University).
Library screening
A human fetal brain derived cDNA library was cloned into the
transcription activator domain vector pJG4–5 (TRP1, ampr) (also
provided by Dr Brent). Expression of fusion proteins is under the
control of a GAL1 promoter. The yeast strain EGY48 (ura3, his3,
trp1, LexAop-leu2)) was cotransformed with pEG202/erbB3, the
cDNA library, and a pSH18-34 (URA3, ampr) reporter plasmid
which provides a LacZ gene with LexA binding sites. 1.4 ´ 106
primary transformants were tested for Leu gene expression on
Gal/SD-His, Trp, Ura, Leu plates. Among 86 Leu-positive clones,
12 yeast clones expressed the lacZ gene in a galactose-dependent
manner as tested by a combination of filter lift b-galactosidase
assays and b-galactosidase assays on Xgal plates.
Determination of complete ebp1 cDNA sequences
The ebp1 cDNA isolated in the two-hybrid system was radiola-
belled by random priming (Pharmacia) and used to screen a human
small-cell lung carcinoma (1688) cDNA library cloned into the
pBK phagemid (a gift of Dr A Doyle, University of Maryland).
After secondary cDNA library screening, we obtained a phage
with a 1.3 kb insert, but without an in-frame termination codon. To
obtain the sequence of the remaining 3¢-end of the ebp1 cDNA,
total RNAs were isolated from AU565, EP62.1 and MDA MB468
human mammary carcinoma cell lines. RNA (1 mg) was reverse-
transcribed using oligo-dT primers and Moloney-murine
leukaemia virus reverse transcriptase at 42°C for 15 min, 95°C for
5 min, and 5°C for 5 min. A first round of PCR was performed
using a primer (sense; 5¢-GGGAATTCTGCGCCAAACAT-
GAACTGCT-3¢) specific for the 3¢-end of the 1.3 kb ebp1 insert,
and Adaptor dT (antisense; 5¢-GGGAATTCGTCGACATC-
GATTTTTTTTTTTTTTTTT-3¢) at 95°C for 1 min, 55°C for 1 min
and 72°C for 1.5 min, for 30 cycles. A second round of PCR was
performed using a primer (sense; 5¢-GGGAATTCATGAGAAG-
GAGGGTGAATTT-3¢) specific for the 3¢-end of the 1.3 kb ebp1
insert, and Adaptor dT (antisense) under the same reaction condi-
tions. The resulting PCR product (0.6 kb) was cloned into the
pCRII vector using a TA cloning kit (Invitrogen) and sequenced
with an Applied Biosystems model 373A Automatic Sequencer.
Northern blotting
Total RNA was isolated from the human mammary carcinoma cell
lines AU565, EP62.1, MDA MB231 and MDA MB468, a human
lung epithelial cell line E6, and a sarcoma cell line SK-LMS-1.
Total RNA (20 mg) was analysed on 1.2% formaldehyde agarose
gels. After transfer of RNA onto nitrocellulose membranes, the
ebp1 cDNA isolated in the two-hybrid system was radiolabelled
by random priming and hybridized to blots at 65°C overnight. A
Human Multiple Tissue Northern blot (Clontech, Palo Alto, CA,
USA) was also hybridized with the radiolabelled ebp1 cDNA
probe at 65°C overnight.
Construction of deletion mutants and in vitro binding
assays
A construct encoding GST-fused erbB3 was prepared by
subcloning erbB3 (aa 665–1339) from pEG202/erbB3 into the
EcoRI and SalI restriction sites of pGEX4T-1 (Pharmacia). Unique
restriction sites (NcoI, SacII, BglII, XhoI, NdeI) in the pGEX-4T-
1/erbB3 were used to create deletion mutants of erbB3 (aa
665–1241, 665–1120, 665–931, 665–822, 665–756 respectively).
Further deletion constructs of erbB3 (aa 665–732, 665–711,
665–690) were created by PCR using appropriate restriction
enzyme adaptors. ErbB3 (aa 756–1339) was generated by blunt
end ligation after EcoRI and NdeI restriction enzyme digestion.
The sequence of the construct was confirmed by automated DNA
sequencing.
GST-wt or mutant erbB3 fusion proteins were expressed in the
BL21 bacterial strain, purified on glutathione Sepharose beads,
and examined by Coomassie blue staining of sodium dodecyl
sulphate polyacrylamide gels (SDS-PAGE). 35S-labelled Ebp1 was
obtained by in vitro transcription/translation using a TNT/T7-
coupled reticulocyte lysate system (Promega). Equal amounts of
GST or GST-erbB3 fusion proteins were incubated with Ebp1 at
4°C for 2 h and analysed by SDS-PAGE and autoradiography.
Immunoprecipitation and immunoblotting
Lysates of AU565 cells were prepared in RIPA buffer (50 mM Tris,
pH 7.4, 150 mM sodium chloride (NaCl), 1% Triton X-100, 1%
deoxycholic acid sodium salt, 0.1% SDS, 100 mg ml–1 phenyl-
methylsulforylfluoride, (PMSF) 1 mM dithiothreitol (DTT), 1 mg
ml–1 aprotinin, 1 mg ml–1 leupeptin). Protein concentrations were
determined using a BioRad kit (BioRad, Richmond, CA, USA).
Equal amounts of protein were precleared overnight with 10 mg of
rabbit IgG and Protein A/G agarose, and immunoprecipitated with
either an anti-erbB3 antibody (C-17, Santa Cruz) or anti ErbB-2
(Oncogene Science, Cambridge, MA, USA) antibody. Proteins
were resolved by SDS-PAGE, transferred to polyvinyldifluoride
(PVDF) membranes, and blotted with either an anti-p38-2G4
monoclonal antibody, a generous gift of Dr E Jost (Radomski and
Jost, 1995), or a horseradish peroxidase (HRP)-conjugated anti-
body to GST-EBP1 (see below). Blots were reprobed with either
the anti-ErbB3 or anti ErbB-2 antibodies as appropriate. In addi-
tion, NIH 3T3 cells, singly expressing human EGFR [a kind gift 
of Dr Michael Klagsburn (Zhang et al, 1996)] were transiently
transfected with a Flag-tagged ebp1-pcDNA3.1 expression vector
using the Fugene 6 Reagent (Boehringer-Mannheim, Indianapolis,
IN, USA). Forty-eight hours after transfection, cells were
immunoprecipitated with either rabbit IgG or a rabbit anti EGFR
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Proteins were resolved and transferred as above. Blots were cut in
half and probed with antibody to the Flag epitope (M2, Sigma,
St Louis, MO, USA), or EGFR (Santa Cruz).
After ligand (HRG, 10 ng ml–1 or EGF, 50 ng ml–1) stimulation,
cytoplasmic fractions of cell lysates were prepared in IP buffer
(50 mM Tris, pH 8.0, 120 mM NaCl, 0.5% NP-40, 100 mg ml–1
PMSF, 1 mM DTT, 1 mg ml–1 aprotinin, 1 mg ml–1 leupeptin) and
subjected to immunoprecipitation as above. For Western analysis,
cell lysates prepared in RIPA buffer were directly resolved by
SDS-PAGE and immunoblotted with a rabbit polyclonal GST-
EBP1 antibody prepared against a purified GST-EBP1 fusion
protein at Covance Laboratories (Danvers, PA, USA).
Immunoperoxidase staining
AU565 cells were plated in 8-chamber Lab-Tek slides (1 ´ 104cells
well–1). Cells were serum starved for 2 days in 0.1% fetal bovine
serum (FBS) containing media. Cells were treated with HRGb1
177–244 (10 ng ml–1) (Genentech, San Francisco, CA, USA) for 5,
10, 15, 30, 60, or 90 min. Cells were stained with either the
anti-p38-2G4 monoclonal antibody or the GST-EBP1 polyclonal
antibody using the appropriate Elite ABC staining kits (Vector,
Costa Mesa, CA, USA).
RESULTS
LexA transcription factor-based yeast two-hybrid
screening
The cytoplasmic domain of erbB3 was subcloned into the pEG202
LexA DNA binding domain vector and the expression of a LexA-
erbB3 fusion protein (around 100 kDa) was determined in lysates
of pEG202/erbB3 transformants by immunoprecipitation and
Western blotting with an antibody against ErbB3. Tyrosine phos-
phorylation blots of ErbB3 immunoprecipitates from pEG202/
ErbB3 transformants revealed that ErbB3 was not tyrosine phos-
phorylated in yeast (Yoo and Hamburger, 1999). This screen was
therefore biased towards the identification of proteins that bind to
ErbB3 in the absence of tyrosine phosphorylation. A human fetal
brain cDNA library was screened for proteins which interact with
the cytoplasmic domain of ErbB3. We isolated 12 positive clones
from 1.4 ´ 106 primary transformants.
The ebp1 clone isolated from the yeast two-hybrid screening
contained a translation initiation codon, a 954 bp ORF, but not a
termination codon. This cDNA also showed a 98% identity with
the nucleotide sequence of the mouse gene Pa2g4 (EMBL
X84789) The first methionine of this cDNA clone corresponded to
the start codon of the mouse protein p38-2G4. To obtain a full
Ebp1, an ErbB-3 binding protein 685
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Figure 1 Immunological detection of Ebp1. Lysates of COS-7 cells (lanes 1,
3, 5) or pBK/Ebp1 transfected COS-7 cells (lanes 2, 4, 6) were separated by
SDS-PAGE, transferred to PVDF membranes and blotted with a polyclonal-
anti GST-EBP1 antibody (lanes 1, 2). Anti-GST-EBP1 antibody was
preincubated with a 100 fold excess amount of purified GST-EBP1
(lanes 3, 4) or GST (lanes 5, 6) before being used for immunoblotting
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Figure 2 Distribution of EBP1 mRNA expression. (A) A multiple tissue blot of RNAs from the indicated organs was probed with an ebp1 cDNA probe as
described. (B) Northern blot analysis of EBP1 expression in human cell lines. AU565 (lane 1), MDA-MB231 (lane 2), and MDA-MB468 (lane 3), mammary
carcinoma cell lines; EP62.1 (lane 4), an erbB2-transfected human mammary epithelial cell line; E6 (lane 5), SV-40 T antigen transformed lung epithelial cell
line; SK (lane 6), the sarcoma cell line SK-LMS-1. Ethidium bromide staining of the gel prior to transfer revealed that equal amounts of RNA had been loaded
(data not shown)
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Lunglength ebp1 cDNA, we screened a cDNA library from a human
small-cell lung carcinoma (1688) cell line and performed reverse
transcription PCR (RT-PCR) of mRNA from the AU565 human
mammary carcinoma cell line (see Methods and Materials). A
1648 nucleotide insert was obtained. This insert contained a termi-
nation signal and another ATG initiation site 5¢ to the ATG of the
original ORF. This larger cDNA shared a 98% nucleotide identity
with the previously isolated human PA2G4 (Genbank U59435)
clone. This cDNA encodes a predicted protein (Ebp1) of 394
amino acid residues which is 100% identical to the protein
predicted to be encoded by the PA2G4 gene. This protein is
also identical to p38-2G4, apart from the additional N terminal 54
amino acids. Like the mouse protein, Ebp1 is a basic protein with
a putative nuclear localization signal in the C-terminus of the
protein (aa 368–373). The protein also contains five putative 
phosphorylation sites (S/T-X-X-D/E) for casein kinase II, and six
putative sites (S/T-X-R/K) for protein kinase C (PKC)-mediated
phosphorylation. An amphipathic helical domain is also predicted
(amino acids 258–313).
An expression plasmid pBK/Ebp1 which encodes amino acids
1–373 of ebp1 was obtained from a human small-cell lung carci-
noma (1688) cDNA library. To determine the size of Ebp1
expressed in mammalian cells, lysates of COS-7 cells or
pBK/Ebp1-transfected COS-7 cells were immunoblotted with a
rabbit antibody prepared against GST-EBP1. This antibody
detected an endogenous 50 kDa Ebp1 protein and an exogenous
protein that migrated at approximately 48 kDa (Figure 1).
Preincubation of anti-GST-EBP1 antibody with excess amounts of
purified GST-EBP1, but not with GST alone, diminished protein
detection (Figure 1).
mRNA expression of ebp1
The distribution of ebp1 mRNA in various normal human organs
was determined by Northern blot analysis (Figure 2A). Two ebp1
transcripts of approximately 1.7 and 2.2 kb were observed in all
organs that were examined, including heart, brain, lung, pancreas,
skeletal muscle, kidney, placenta and liver. The expression of ebp1
mRNA in various ErbB-expressing carcinoma cell lines was also
examined (Figure 2B). Two ebp1 transcripts of 1.7 and 2.2 kb
were detected in the human breast carcinoma cell lines AU565
(ErbB-1, 2, 3+), MDA MB468 (ErbB-1, 3+) and MDA MB231
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Figure 3 In vitro and in vivo interaction of Ebp1 and ErbB receptors.
(A) Interaction of in vitro translated (IVT) 35S-labelled Ebp1 with GST-ErbB-3665–1339. Ebp1 alone (20% of the input used for the binding assays) is shown in lane
1. Purified GST (lane 2), or purified GST-ErbB-3 fusion proteins (lane 3) were incubated with equal amounts of Ebp1. The IVT product of ebp1 is marked. The
large arrow indicates the position of the 45 kDa marker. (B) AU565 cell lysates were immunoprecipitated with rabbit IgG (lane 1), an anti-ErbB-3 rabbit antibody
(lane 2), or an anti ErbB-2 antibody (lane 3) and analysed by sequential immunoblotting (IB) with either anti-ErbB-2 or 3 antibodies (top) or a HRP-conjugated
anti GST-EBP1 antibody (bottom). (C) AU565 cell lysates were immunoprecipitated with the anti-GST-EBP1 antibody (lane 1) or rabbit IgG (lane 2) and
analysed by sequential immunoblotting with either an ErbB-3 antibody (top) or a murine anti p38-2G4 antibody (bottom) as indicated. (D) NIH3T3 cells,
overexpressing human ErbB-1, were transiently transfected with an expression vector encoding a Flag-tagged Ebp1 protein. Cell lysates were
immunoprecipitated with either rabbit IgG (lane 2) or rabbit anti EGFR antibody (lane 3). Cell lysates was also directly loaded onto the gels (lane 1). Cell lysates
were resolved by SDS-PAGE and analysed by immunoblotting (IB) with a murine anti-Flag antibody (top) or a rabbit anti EGFR antibody (bottom)
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D(ErbB-1, 3+), an ErbB-2 overexpressing, ErbB3-expressing
mammary epithelial cell line 62.1 (Pierce et al, 1992), an ErbB-2
overexpressing, ErbB-3 expressing human lung epithelial cell line
E6 (Noguchi et al, 1993) and a heregulin-producing sarcoma cell
line SK-LMS-1.
In vitro and in vivo interactions of Ebp1 and ErbB-3
We investigated the interaction of the Ebp1 protein with ErbB-3 in
vitro. Purified GST or a GST-ErbB-3 (aa 665-1339) fusion protein
was incubated with the 35S-labelled in vitro translation product of
pBK/Ebp1 (Figure 3A). GST-ErbB-3, but not GST alone, bound
an approximately 48 kDa ebp1 translation product. The interaction
between Ebp1 and ErbB-3 was further investigated in vivo in the
AU565 mammary carcinoma cell line. AU565 cells express ErbB-
1, 2 and 3 protein and ErbB-4 mRNA (Yoo and Hamburger, 1998).
Protein immunoblot analysis with an HRP-conjugated GST-EBP1
antibody demonstrated the presence of an approximately 50 kDa
Ebp1 protein in ErbB-3, but not ErbB-2, immunoprecipitates
(Figure 3B). Conversely, ErbB-3 was present in Ebp1 immuno-
precipitates (Figure 3C). As the juxtamembrane domain of the
EGFR is more closely related to that of ErbB-3 (54% identity), we
examined the ability of EGFR to bind Ebp1. NIH3T3 cells, over-
expressing human EGFR, were transiently transfected with a Flag
tagged Ebp1 cDNA. Cell lysates were immunoprecipitated with
antibody to the EGFR. Flag-tagged Ebp1 did not co-immuno-
precipitate with the EGFR (Figure 3D).
To identify the region of ErbB-3 that is required for binding
to Ebp1, deletion mutants of GST-ErbB-3 were constructed
(Figure 4A) and tested for binding to in vitro translated Ebp1. A
series of deletion mutants of ErbB-3 [aa 665–1241, 665–1120,
665–931, 665–822 (data not shown)] and 665–756, 665–732,
Ebp1, an ErbB-3 binding protein 687
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Figure 4 Mapping of the erbB3 binding domain for EBP1. (A) Diagram of truncated GST-ErbB-3 fusion proteins and their in vitro binding with Ebp1. (B) Equal
amounts of in vitro translated 35S radiolabelled Ebp1 were incubated with GST alone (lane 2), or equal amounts of GST/erbB3 (665–756) (lane 3), GST/erbB3
(665–732) (lane 4), GST/erbB3 (665–711) (lane 5), GST/erbB3 (665–690) (lane 6), GST/erbB3 (756–1339) (lane 7). The amount of GST or GST-erbB3 fusion
proteins were determined by SDS-PAGE and Coomassie blue staining in all experiments. Lane 1, IVT products alone (20% of the input for the binding assays).
(C) Equal amounts of in vitro translated 35S radiolabelled Ebp1 (lane 1) were incubated with GST-ErbB-3 (aa 665–690) in the presence of a 75-fold (lane 2),
250-fold (lane 3), 500-fold (lane 4), or 1000-fold (lane 5) excess of an ErbB-3 competing peptide (aa 665–690). (D) Equal amounts of in vitro translated 35S
radiolabelled Ebp1 were incubated with GST alone, or equal amounts of alanine scanning mutants (A1–A5) of GST/ErbB-3 (665–690) (=D1). Upper panel,
amino acid sequences of ErbB-3 (665–690) and A1 to A5 are shown665–711, 665–690 maintained the ability to bind Ebp1 (Figure
4B). GST-ErbB-3665–690, which contains the first 26 amino acids of
the cytoplasmic domain of erbB3, was the smallest mutant to
retain the ability to bind to EBP1. GST-ErbB3756–1339, which
contained the full cytoplasmic domain of erbB3 except the first 
92 amino acids (aa 665–756), failed to bind EBP1, indicating that
the 26 amino acids of the juxtamembrane domain of erbB3 
(aa 665–690) were required for binding to EBP1. ErbB-3 binding
to Ebp1 was competed by a purified peptide specific for ErbB-3
(aa 665–690) (Figure 4C).
To further characterize the binding domain for Ebp1, a series of
alanine scanning mutants of GST-ErbB-3665–690 (A1–A5) was
created, and tested for binding to Ebp1 (Figure 4D). Mutants A1,
A2 and A3 lost, but mutant A4 retained, the ability to bind Ebp1,
indicating that some of the first 15 amino acids of the juxtamem-
brane domain of ErbB-3 (aa 665–680) were essential for binding
to Ebp1. In addition, the binding of mutant A5 was somewhat
reduced compared to that of the controls.
Ebp1 translocates into the nucleus after HRG
incubation
A putative nuclear localization signal is present at the C-terminal
end of the Ebp1 protein. We therefore examined the subcellular
localization of Ebp1 in serum-starved and HRG- (10 ng ml–1)
stimulated AU565 cells by immunoperoxidase staining using the
anti-p38-2G4 monoclonal antibody. Ebp1 protein was primarily
localized in the cytoplasm (> 90% of cells) of serum starved cells
(Figure 5A). Treatment of AU565 cells with HRG altered the
subcellular distribution of Ebp1. Translocation of Ebp1 protein
into the nucleus was observed after 5 min (60.5% in the nucleus),
and continued up to 90 min (93.1% in the nucleus) after HRG
treatment (Figure 5B). Similar results were obtained using the
rabbit antibody to GST-EBP1 (data not shown).
To substantiate our morphological findings, we next examined
the effect of HRG on the binding of ErbB-3 to Ebp1. AU565 cells
were treated with HRG (10 ng ml–1) or EGF (50 ng ml–1) for 15
min and the interaction of ErbB-3 and Ebp1 was analysed by
immunoprecipitation (Figure 5C). Treatment of AU565 cells with
HRG caused a reduction (as determined by densitometry) of
binding between Ebp1 and ErbB-3, providing biochemical
evidence of HRG induced dissociation of Ebp1 from ErbB-3.
Treatment of cells with EGF did not affect Ebp1 binding to ErbB-
3. The ratio of Ebp1 to ErbB-3 for control, heregulin and EGF-
treated cells was 1.6, 0.3 and 1.3 respectively.
DISCUSSION
ErbB-3, despite its impaired tyrosine kinase activity, is a func-
tional receptor for HRG. ErbB-3–HRG interaction leads to cellular
proliferation or differentiation by stimulation of a cascade of
signalling events (Bacus et al, 1993; Fedi et al, 1994; Sliwkowski
et al, 1994). To better understand HRG-mediated ErbB-3
signalling pathways, we performed a yeast two-hybrid screening
with the cytoplasmic domain of ErbB-3 to isolate proteins that
interact with ErbB-3. We report here that Ebp1, the protein
predicted to be encoded by the PA2G4 gene, is an ErbB-3-inter-
acting protein, which translocates into the nucleus upon HRG
stimulation.
The PA2G4 gene is a member of the recently described PA2G4
family (Lamartine et al, 1997). The prototype of this family, the
mouse p38-2G4 gene, was isolated by generating monoclonal anti-
bodies against DNA binding proteins. The sequence of the human
PA2G4 cDNA predicts a protein of 394 amino acids and approxi-
mately 45 kDa molecular weight, which has a longer N-terminal
region than mouse p38-2G4 protein. Both the in vitro translation
product and the in vivo expressed protein of our slightly truncated
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Figure 5 HRG-induced translocation of Ebp1. The cellular localization of
Ebp1 was visualized by immunoperoxidase staining using an antibody
against p38-2G4. AU565 cells were incubated with antibody against p38-2G4
in the absence (A) or presence (B) of HRG (10 ng ml–1, 15 min). (C) HRG-
induced dissociation of Ebp1. AU565 cells were left untreated (–) (lane 1),
stimulated with HRG (10 ng ml–1, 15 min) (lane 2), or stimulated with EGF 
(50 ng ml–1, 15 min) (lane 3). ErbB-3-associated Ebp1 was analysed by
ErbB-3 immunoprecipitation (IP) and sequential immunoblotting (WB) with
antibodies against p38-2G4 (top) and ErbB-3 (bottom). Representative of
three trialspBK cDNA clone migrate at a somewhat higher molecular weight
than predicted. Using antibodies generated against both a GST-
EBP1 fusion protein and the murine p38-2G4 protein (data not
shown), we detected an endogenous full-length protein of
approximately 50 kDa from AU565 and COS-7 cell lysates. Ebp1
contains five putative phosphorylation sites (S/T-X-X-D/E) for
casein kinase II, and six putative sites (S/T-X-R/K) for PKC-
mediated phosphorylation. Thus, the changes in electrophoretic
mobility may be due to post-translational phosphorylation.
ErbB-3 bound Ebp1 via its juxtamembrane domain. In the
experiments presented here, ErbB-2, which has a 38% amino acid
identity in the 26 amino acid binding region, did not bind to Ebp1.
The EGFR, singly transfected into NIH 3T3 cells, also did not bind
to Ebp1. ErbB3 and EGFR have a 54% amino acid identity in the
26 amino acid binding region with 6/7 positively charged residues
remaining the same. Thus, it is unlikely ErbB-3-Ebp1 binding is
non-specific.
Ebp1 dissociated from ErbB-3 after heregulin treatment. Ebp1
did not dissociate from ErbB-3 after EGF treatment. This is some-
what surprising as EGF treatment of MDA 468 cells results in
tyrosine phosphorylation of ErbB-3 (Kim et al, 1994). However,
EGF or HRG treatment result in phosphorylation of different
amino acid residues on ErbB receptors (Olayioye et al, 1998). In
addition, HRG, but not EGF, treatment may have modified Ebp1
itself leading to dissociation from ErbB-3. Modification of Ebp1,
rather than ErbB-3, by heregulin may lead to dissociation.
Although we have demonstrated nuclear localization of Ebp1
after HRG stimulation, we have not yet directly demonstrated the
function of the Ebp1 protein in the nucleus. Amino acid homology
comparison of the Ebp1 protein shows a 42% homology with a
yeast curved DNA binding protein (Yamada et al, 1994). The
mouse homologue p38-2G4 was originally cloned from Ehrlich
ascites tumour cells using a set of monoclonal antibodies which
specifically recognizes DNA binding proteins. Biochemical
analysis suggested p38-2G4 bound directly or, via a protein
complex, to DNA (Radomski and Jost, 1995). These results
suggest that Ebp1 may be involved in the regulation of cell growth
or differentiation in mammary epithelial cells through putative
DNA binding properties after translocation into the nucleus.
Ligand-control of gene activation by directly inducing translo-
cation of membrane receptor bound regulatory proteins to the
nucleus is an emerging area in signal transduction. For example, a
zinc finger protein, ZPR1, which associates with unstimulated
EGFR, and MADR2, a substrate for the transforming growth
factor-b (TGF-b) receptor, both dissociate from their receptors and
translocate into the nucleus after ligand stimulation (Macias-Silva
et al, 1995; Galcheva-Gargova et al, 1996). In Drosophila,
Suppressor of Hairless (Su(H)) also directly associates with intra-
cellular ankyrin repeats of the receptor Notch and mediates
signalling by translocation into the nucleus after receptor stimula-
tion (Jarriault et al, 1995). Although Ebp1 does not resemble these
proteins structurally, these proteins may together constitute a new
functional class of signalling molecules.
In conclusion, we report here that the Ebp1 protein, which binds
to the juxtamembrane domain of ErbB-3, translocates into the
nucleus after HRG stimulation. The biological relevance of
ErbB-3 interaction with Ebp1 and the mechanisms of Ebp1 disso-
ciation from ErbB-3 remain to be elucidated.
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